A/Prof Michael Jones

Welcome to the webpage for A/Prof Michael Jones, a dedicated radiation oncologist located at Hobart, Melville Street, 2 in Australia. As a highly committed healthcare professional, A/Prof Michael Jones strives to achieve the best outcomes for his patients.

A/Prof Michael Jones is a Clinical Associate Professor and radiation oncologist at Icon Cancer Centre Hobart. He obtained his Bachelor of Medicine, Bachelor of Surgery (MBBS) degree from the Australian National University. Following his studies, he completed his radiation oncology training in New South Wales and became a fellow of the Royal Australian and New Zealand College of Radiologists (RANZCR) in 2016. A/Prof Michael Jones further honed his skills by undertaking a clinical research fellowship at the prestigious Princess Margaret Cancer Centre in Toronto, Canada. He holds a Master of Public Health and a PhD in Medicine, showcasing his dedication to advancing medical knowledge and patient care.

In addition to his role at Icon Cancer Centre Hobart, A/Prof Michael Jones also serves as a staff specialist radiation oncologist and Director of Training at the Royal Hobart Hospital. He is also an esteemed Clinical Associate Professor at the Tasmanian School of Medicine, University of Tasmania. A/Prof Michael Jones is a valued member of the executive committee of the Faculty of Radiation Oncology Genito-Urinary Group (FROGG). His passion for research and clinical trials is evident, as he has been awarded numerous competitive research grants and has published in leading international radiation oncology journals. A/Prof Michael Jones is currently the principal investigator for several active clinical trials in Hobart, further showcasing his dedication to advancing cancer treatment.

A/Prof Michael Jones specializes in the treatment of a wide range of cancers, including prostate cancer, breast cancer, lung cancer, brain cancer, lymphoma, and gastrointestinal cancer (oesophagus, stomach, pancreas, colon, rectum, and anal canal). With his extensive expertise and compassionate approach, patients can trust that they are in capable hands when seeking treatment from A/Prof Michael Jones.

One notable clinical trial led by A/Prof Michael Jones is the Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP). This trial aims to improve treatment outcomes for patients with high-risk prostate cancer by investigating the effectiveness of darolutamide in combination with standard therapy.

If you are seeking a highly skilled and dedicated radiation oncologist in Hobart, look no further than A/Prof Michael Jones. With his commitment to patient care, extensive experience, and involvement in cutting-edge research, A/Prof Michael Jones is a trusted healthcare professional who strives to achieve the best outcomes for his patients.